Critical insights into the evolving drug‐approval process in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Critical insights into the evolving drug‐approval process in China

Published:2024-01-02 Issue: Volume: Page:
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Nikanjam Mina¹,Kurzrock Razelle²³^ORCID

Affiliation:

1. Division of Hematology‐Oncology University of California San Diego La Jolla California USA

2. Medical College of Wisconsin Cancer Center Milwaukee Wisconsin USA

3. Worldwide Innovation Network (WIN Consortium) for Personalized Cancer Therapy Paris France

Abstract

Efforts have been put forward to improve the therapeutic development process in China, and more novel therapies have been approved in recent years. It is important to develop and test novel therapies in China given differences in metabolism and tolerance compared with other populations.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference16 articles.

1. Characteristics of clinical trials of new oncology drugs approved in China

2. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020

3. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics

4. US Food and Drug Administration (FDA).FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.FDA;2022. Accessed November 17 2023.https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐approves‐pemigatinib‐relapsed‐or‐refractory‐myeloidlymphoid‐neoplasms‐fgfr1‐rearrangement

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP